Equities
Health CareMedical Equipment and Services
  • Price (USD)73.80
  • Today's Change-0.42 / -0.57%
  • Shares traded1.62m
  • 1 Year change-3.09%
  • Beta1.0159
Data delayed at least 15 minutes, as of Dec 07 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics segment offers a range of diagnostics products, such as ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. Its Breast Health segment offers a portfolio of solutions for breast cancer care, primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment offers a range of products, such as NovaSure Endometrial Ablation System, MyoSure Hysteroscopic Tissue Removal System and Fluent Fluid Management system as well as its Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, and the Fluoroscan Insight FD mini C-arm.

  • Revenue in USD (TTM)4.86bn
  • Net income in USD1.30bn
  • Incorporated1990
  • Employees6.94k
  • Location
    Hologic Inc250 Campus DriveMARLBOROUGH 1752United StatesUSA
  • Phone+1 (781) 999-7300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.hologic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Henry Schein, Inc.12.61bn638.23m10.93bn21.60k17.553.0212.540.86714.594.5990.7426.701.494.888.24583,635.307.706.2712.9911.2130.2329.995.184.800.996736.380.17850.0022.551.3956.714.492.40--
Teleflex Incorporated2.79bn412.27m11.07bn14.00k27.112.8417.243.968.718.7159.0283.040.40512.507.07199,639.905.985.576.536.1054.7055.2214.7513.901.5211.290.304817.9710.748.5144.4715.396.150.00
Align Technology, Inc.3.86bn510.76m14.53bn22.54k28.803.9322.983.766.466.4648.9747.300.66844.184.51171,438.308.8325.1212.8336.5071.4473.4013.2230.361.20--0.000.0059.9029.63-56.5332.4141.55--
Cooper Companies Inc3.22bn430.60m15.45bn12.00k36.232.1820.194.808.648.6464.62143.670.30431.845.97268,291.704.0714.094.6015.9965.3865.0313.3734.480.709563.360.28920.338620.228.241,135.1960.807.030.00
ABIOMED Inc1.07bn266.76m17.04bn2.00k64.9611.0957.9015.875.825.8223.4134.090.66582.1311.67536,243.6016.5416.9117.9118.7581.3282.1324.8423.457.17--0.000.0021.7418.30-39.4721.24-6.64--
West Pharmaceutical Services Inc.2.91bn633.80m17.40bn10.07k28.297.0423.505.988.318.2738.1133.390.90074.526.05289,021.4019.0814.1122.6416.7840.4535.6121.1916.012.89280.860.078113.6131.8913.4190.7635.688.297.09
Hologic, Inc.4.86bn1.30bn18.25bn6.94k14.503.7610.533.755.125.1219.1619.730.54063.296.23700,273.6014.479.4616.5611.3862.0059.9826.7817.393.4538.690.36840.00-13.669.72-30.4311.503.40--
Steris PLC4.78bn-8.14m18.32bn16.42k--3.1629.803.84-0.1063-0.106347.4958.100.42954.336.19290,869.90-0.08395.33-0.09075.8445.2243.08-0.195310.081.427.620.342339.1147.5511.90-38.6317.2710.719.17
Insulet Corporation1.24bn16.80m20.83bn2.30k1,359.9948.66264.7016.760.22060.220617.686.160.5971.517.88540,565.200.80670.19890.93270.225564.4765.321.350.31743.002.240.76670.0021.4924.52147.06--40.87--
Zimmer Biomet Holdings Inc7.15bn338.40m25.47bn19.50k75.552.0819.533.561.611.3234.0858.360.31550.93015.36366,805.101.501.031.691.1669.7971.164.743.311.057.200.318177.3511.560.4339400.007.13-1.880.00
Baxter International Inc14.74bn-2.38bn25.97bn60.00k--4.69--1.76-4.72-4.7229.1010.980.61713.996.37245,666.70-9.906.03-11.667.2236.3841.58-16.0410.021.385.220.746538.319.524.7016.52-23.700.658916.53
Data as of Dec 07 2022. Currency figures normalised to Hologic Inc's reporting currency: US Dollar USD

Institutional shareholders

44.27%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202227.42m10.98%
T. Rowe Price Investment Management, Inc.as of 30 Sep 202224.65m9.87%
BlackRock Fund Advisorsas of 30 Sep 202215.07m6.04%
SSgA Funds Management, Inc.as of 30 Sep 202211.55m4.63%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20227.25m2.91%
Geode Capital Management LLCas of 30 Sep 20225.83m2.34%
Macquarie Investment Management Business Trustas of 30 Sep 20225.83m2.34%
Wellington Management Co. LLPas of 30 Sep 20224.69m1.88%
Victory Capital Management, Inc. (Investment Management)as of 30 Sep 20224.27m1.71%
Arrowstreet Capital LPas of 30 Sep 20223.96m1.59%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.